Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IDVV News: IEC Announces Update on Winners Waygers AI Powered Sports Handicapping Assistant
Las Vegas, Nevada--(Newsfile Corp. - September 10, 2024) - International Endeavors Corp. (OTC PINK: IDVV) ("IEC"), a technology holdings company announced that its artificial intelligence (AI) powered sports handicapping assistant has received additional pro subscribers, and its free beta version has topped 4000 subscribers.
Previously the company announced the launch of http://winnersaygers.com, a one of a kind artificial intelligence (AI) powered sports handicapping program in beta mode. Today we are pleased to announce that the free beta service has already received 4000 subscribers.
Current subscribers are being given picks that the AI is generating for the current NFL season, and plans are to convert subscribers to several paid options towards the end of October as the AI learns more data during the current season and becomes more efficient in its strategy. Last season the AI had over a 60% win rate, with an increasingly better win rate as the season progresses and the AI is able to use more up to date information. The current focus is building subscribers while perfecting the AI's thought process.
We have received additional subscribers for the professional AI handicapping version. Used by professional handicappers that helped to develop the tools and datasets for the AI. The pro tools do not make picks for professionals, but instead help them to acquire data at a much faster pace and allow them to increase their action. We anticipate reaching up to 100 subscribers by year end. Due to that nature of the handicapping community, Pro subscribers are acquired by referrals. Each paying a negotiable signup fee of up to $10,000 per license along with a monthly subscription of $1000 to $2000.
Winners Waygers spokesperson Marrion Lewis stated "We are on track with offering the service to the mainstream. Converting the pro version to a more user friendly mainstream style has been an undertaking, but one that our team is doing well. We're confident that a product will be there that can revolutionize the industry."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/222813_21b8d136c42aeaa5_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222813
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/222813/130
$AVRW Avenir Wellness Solutions™ ($AVRW) Skin Care Products are Sold at Walmart $WMT , Target $TGT , CVS Health $CVS , and Amazon $AMZN Retail Outlets. Accelerating Sales for Superior Anti-Aging Skin Care Line with Direct Endorsement of Nicole Kidman
Click here:
https://www.einpresswire.com/article/660866879/accelerating-sales-for-superior-anti-aging-skin-care-line-with-direct-endorsement-of-nicole-kidman-stock-symbol-avrw
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.
This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$CATV On The Brink Of Major Biotech Acquisition
https://www.degenmag.com/post/catv-on-the-brink?fbclid=IwZXh0bgNhZW0CMTEAAR3JeK6FnTkxWKrJ_DGdNQIetrmaeLVZWu95CgJQbUnn4-kVcxLqS6KRYKk_aem_4HuKAP7r6qqO5vYOWbQGtA
$RENB News: Renovaro, Inc. Announces $10 million in Equity Committed
LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.
“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$SHOT: Safety Shot Partners with Capital Drugs To Launch World's First Beverage To Reduce Blood Alcohol Content in 300 Pharmacies Across the Country
The First of its Kind Vitamin-Packed, Wellness Beverage Brand Continues to Amplify its In-Store Availability Nationwide
JUPITER, Fla., June 6, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company), announced today its partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States.
Entering a key market for Safety Shot consumers, Capital Drugs is known for providing a wide range of pharmaceutical services and products tailored to specific health and wellness needs. Capital Drugs offers traditional pharmacy and clinical services in tandem with alternative medicine options such as supplements, vitamins, and homeopathic products.
"Entering Capital Drugs pharmacies is an integral next step in furthering Safety Shots key messaging and purpose of operating as a functional wellness beverage," said Josh Wagner, Chief Revenue Officer at Safety Shot. "Expanding on-shelf availability and having the product available for purchase in key locations like Capital Drug pharmacies is the brand's core mission, introducing the first-of-its-kind beverage to a like-minded consumer audience."
This latest affiliation aligns with the brand's comprehensive nationwide availability rollout and partnership expansion plan. This announcement comes on the heels of its Northeast expansion across New York and New Jersey through boutique broker Prime CBS and additional partnerships with GoPuff, BevMo and more.
About Safety Shot, Inc
Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.
SOURCE Safety Shot
$CCTG - CCSC Technology capabilities include: Turn-key service of manufacturing complex cable & wire harness assemblies
Click here:
https://ccsc-interconnect.com/html/aboutus/capabilities/
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
$GNPX: Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024
Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations
AUSTIN, Texas, May 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).
"We are excited to take this next step in our fight against lung cancers as we work to advance an innovative therapy that we believe provides hope to patients suffering with ES-SCLC, an especially aggressive form of lung cancer that has extremely limited treatment options," said Ryan Confer, President and Chief Executive Officer at Genprex. "With a median progression free survival (PFS) of 5.2 months, ES-SCLC has a particularly poor prognosis. Additionally, patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. With such limited benefit from current treatments, we believe the combination of REQORSA and Tecentriq can provide a promising new therapeutic option for the treatment of small cell lung cancer."
"The Phase 1 dose escalation portion of the Acclaim-3 study is expected to determine the maximum tolerated dose for the Phase 2 expansion study," stated Mark Berger, M.D., Chief Medical Officer of Genprex. "The favorable results from our Phase 1 Acclaim-1 study in non-small cell lung cancer (NSCLC) enabled us to shorten the Phase 1 portion of Acclaim-3. This should allow us to complete the Phase 1 portion of the study during the second half of 2024 and to advance more quickly into the Phase 2 expansion portion of Acclaim-3 in the second half of 2024. We look forward to providing study updates as we advance this potentially life-saving therapy to benefit patients battling ES-SCLC."
Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. REQORSA contains a plasmid that expresses TUSC2, a tumor suppressor gene protein. Nearly 100% of SCLCs have reduced or no TUSC2 protein expression, and 41% completely lack TUSC2 protein expression. Nonclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq.
About the Acclaim-3 Clinical Trial
The Acclaim-3 clinical trial is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC. The Acclaim-3 clinical trial will enroll patients who did not develop tumor progression after receiving Tecentriq and chemotherapy as standard initial treatment, and who are therefore eligible for maintenance therapy.
The Phase 1 dose escalation portion of the Acclaim-3 clinical study is expected to enroll up to 12 patients at approximately ten U.S. clinical sites to determine the Maximum Tolerated Dose (MTD). If no dose limiting toxicities occur during the Phase 1 study, the highest dose evaluated will be the Recommended Phase 2 Dose. The Phase 2 portion of the study is expected to enroll approximately 50 patients at ten to fifteen U.S. sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. Genprex expects to initiate the Phase 2 expansion study in the second half of 2024.
The primary endpoint of the Phase 2 portion of the trial is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq treatment in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up.
Genprex has received U.S. Food and Drug Administration (FDA) Ophran Drug and Fast Track designations for Reqorsa® Immunogene Therapy, in combination with Genentech, Inc's Tecentriq® in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Additional information about the Acclaim-3 clinical trial can be found by visiting ClinicalTrials.gov.
About Reqorsa® Immunogene Therapy
Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy for NSCLC and SCLC consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid-based molecules in a lipoplex form (Genprex's Oncoprex® Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. In addition, REQORSA disrupts the metabolism of cancer cells by decreasing glycolysis and ATP production in cancer cells with decreased TUSC2.
Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on current therapies for patients with NSCLC, SCLC, and possibly other cancers.
Tecentriq® is a registered trademark of Genentech, Inc.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy, is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.
"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."
The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.
Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.
By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.
"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."
RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.
About Renovaro:
Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:
https://techbullion.com/avram-miller-talks-ab...es-with-ai
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
https://www.renovarogroup.com
https://www.renovarobio.com
https://www.renovarocube.com
About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
https://www.cyclomics.com/
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$RENB News: RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo.
Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, we believe the acquisition of Cyclomics into the Renovaro family will further strengthen our ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease. "We believe that this combination can transform the landscape of patient care both for early detection as well as for monitoring continuously the therapeutics given,” according to Dr. Coenraad K. van Kalken (MD/PHD), Chief Commercial Officer of RenovaroCube.
RenovaroCube's open architecture Artificial Intelligence platform, known as the Cube, currently houses over 3600 high-performance biomarker panels for 13 different cancers. This molecular differential AI platform utilizes multi-omic analysis combined with proprietary algorithms and when coupled with Cyclomics' groundbreaking 4th generation molecular technology, shall be able to decode multi-omic data from just a single vial of blood. "We will work with Cyclomics from ‘strength to strength’ providing combined technologies, expertise, and resources which will make us unique and offers what we believe will be an unprecedented accuracy in non-invasive early cancer detection,” added Dr. Henk Viëtor (MD/PHD).
Cyclomics has pioneered a groundbreaking diagnostic method named ‘CyclomicsSeq’ for monitoring early cancer recurrence, utilizing Oxford Nanopore sequencing technology they have created an assay in partnership with Oxford Nanopore that provides detection of even a single ctDNA molecule in blood with nearly 100% accuracy. Additionally, Cyclomics' OmniOmics 4th generation technology enables reliable, fast, and ultra-sensitive early detection of cancer or recurrence thereof using next-generation whole genome sequencing.
"We are excited to join forces with Renovaro to drive the next wave of innovation in molecular biology integrated into an advanced proprietary AI/ML platform," commented Alessio Marcozzi, CSO of Cyclomics. "This combination reflects our shared commitment to pushing the boundaries of what is possible in our respective fields."
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
$GDHG - The global theme park market is a behemoth, projected to reach a staggering US 87.69 billion by 2031, with a Compound Annual Growth Rate exceeding 4.1%. Asia Pacific is The dominant player, driven by rapid economic growth and a growing middle class, particularly in China.
$GDHG - The global theme park market is a behemoth, projected to reach a staggering US 87.69 billion by 2031, with a Compound Annual Growth Rate exceeding 4.1%. Asia Pacific is The dominant player, driven by rapid economic growth and a growing middle class, particularly in China. pic.twitter.com/G03nMaBuO2
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 16, 2024
$GVH News: Globavend Holdings Limited Enters Into a US$20,000,000 Equity Line of Credit Facility to be Registered on Form F-1
PERTH, AUSTRALIA, March 18, 2024 (GLOBE NEWSWIRE) -- Globavend Holdings Limited (Nasdaq: GVH) (the “Company” or “Globavend”), an emerging e-commerce logistics provider, is pleased to announce that it has entered into a US$20,000,000 equity purchase agreement (the “Equity Purchase Agreement”) with Square Gate Capital Master Fund, LLC – Series 1 (“Square Gate”), as well as a registration rights agreement (“Registration Right Agreement”) related thereto. Pursuant to the terms of the Registration Rights Agreement, the Company will register the Company’s ordinary shares (the “Shares”) issuable to Square Gate under the Equity Purchase Agreement for public resale.
Globavend will have the right, but not the obligation, to sell to Square Gate up to US$20,000,000 worth of its Shares at Globavend’s sole discretion over the next 36 months, subject to certain conditions precedent and other limitations. Square Gate will have the obligation to purchase the Shares a price determined in accordance with certain formulas set forth in the Equity Purchase Agreement and subject to certain dollar caps.
Wai Yiu Yau, CEO of Globavend stated “This equity line facility provides Globavend with a viable long-term platform to grow its existing operations, expand its e-commerce logistics services into different verticals of the logistics supply chain, enhance its business presence in Australia, New Zealand and Hong Kong, and capitalize on other potential business opportunities. We are always mindful of the best interests of our shareholders and are committed to deliver solid financial performance for the company in 2024 and beyond.”
About Globavend Holdings Limited
Globavend Holdings Limited is an emerging e-commerce logistics provider offering end-to-end logistics solution in Hong Kong, Australia and New Zealand. The Company’s customers are primarily enterprise customers, being e-commerce merchants, or operators of e-commerce platforms, in providing business-to-consumer (B2C) transactions. As an e-commerce logistics provider, the Company provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution, from pre-carriage parcel drop off to parcel consolidation, air-freight forwarding, customs clearance, on-carriage parcel transportation and delivery.
Forward-Looking Statements
This press release contains certain forward-looking statements, including statements with regard to the Company’s proposed transaction and the future potential of the Company. Words such as “will,” future,” “expects,” “believes,” and “intends,” or similar expressions, are intended to identify forward-looking statements. Forward-looking statements are subject to inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed transaction discussed above will be completed on the terms described or achieve the objectives contemplated. Our ability to utilize the financing platform effectively and successfully are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, the failure of customary conditions precedent and the risk factors and other matters set forth in our annual report on Form 20-F. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
For investor and media inquiries, please contact:
Company Info:
Globavend Holdings Limited
Wai Yiu Yau, Chairman and CEO
project@globavend.com 61 08 6141 3263
https://www.globenewswire.com/newsroom/ti?nf=OTA2NDkzNiM2MTQwMDkzIzUwMDExOTk3MQ==
https://ml.globenewswire.com/media/MjM0ZWI4MTEtYjI1Zi00ZTg5LTgzZDktOGQ3YjYzMDNmNWFmLTUwMDExOTk3MQ==/tiny/Globavend-Holdings-Limited.png
Source: Globavend Holdings Limited
$AVRW is due to report its year end financial results by March 31st which should demonstrate that the company is on a positive revenue growth curve as all the official news has indicated. From the most recent update issued on February 13th we can expect good news for all of 2024. Note the commentary from the CEO
-----------------------------------------------------------------------------------------------------------
Overall, Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
February 13, 2024 News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$RWGI: Rodedawg Intl. Ind, Inc. (OTC: RWGI) Provides Shareholder Updates
Costa Mesa, CA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Rodedawg International Industries, Inc. (OTC: RWGI) proudly announces the Company, through our wholly owned subsidiary, Parabola Mgmt. LLC, has completed and submitted the application as a licensed California cannabis distributor in Coachella, California. Chris Swartz, CEO, states “We are proud to inform our shareholders that we have been making noteworthy progress toward having our licensed cannabis distribution center become an integral revenue generating operating unit of Rodedawg. As per licensing requirements, the Company paid for insurance and bonding, built fencing, installed electricity, and installed security cameras. Our recent acquisition of Parabola Mgmt., LLC coupled with this completed application has the company be on track with its first quarter 2024 milestones as per the Company roadmap. We will continue to keep shareholders apprised of the progress as this new facility will expand the revenues of the Company. We are confident that our strategically planned roadmap of expansion via acquisitions and mergers will increase 2024 revenues to meet and potentially exceed our stated goal of 7 million annually”.
Chris Swartz continues, "We couldn't have done it without this amazing team. Their hard work is making this project a success."
Mr. Swartz concludes “We will continue to provide regular updates for our shareholders as we complete our 2024 roadmap milestones during this 1st Quarter 2024. Once again, we continue to thank our loyal shareholders for their ongoing support as we create Rodedawg to becoming an industry leader in the licensed cannabis market.”
About Rodedawg International Industries, Inc.
Rodedawg International Industries, Inc. (OTC: RWGI) is focused on providing management services, acquisitions and restructuring resources throughout the regulated California cannabis market. We are a trusted partner and asset to licensed cultivation, distributors, manufacturers, and retail dispensaries.
Please note the company Twitter address is https://twitter.com/RWGImerger for regular updates.
About Budding Horizon, LLC
Budding Horizon, LLC is a California Limited Liability Company with offices in Orange County, California. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://buddinghorizon.com/
About Brother Buds™
Brother Buds is a cannabis delivery service based in Costa Mesa, California. During the month of July 2023, the Rodedawg will operate Brother Buds under a non-storefront cannabis delivery license. The cannabis delivery service will focus on Los Angeles County, Orange County, and norther San Diego County in the demographic area of 23.86 million in 2019. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://BrotherBuds.com
Make sure to follow us at https://twitter.com/BrotherBudsOC
About Elixicure
"Elixicure is a leading provider of manufacturing and capsule encapsulation services. We offer a wide range of services to meet the diverse needs of our clients, including capsule encapsulation, formulation, manufacturing, labeling and bottle filling. Our state-of-the-art facilities and experienced team of professionals allow us to deliver high-quality products and exceptional customer service. Whether you are looking for small-scale or large-scale production, we have the expertise and capabilities to meet your needs. Contact us today to learn more about how we can support your manufacturing and encapsulation needs.
The company website is https://elixicure.com/
Make sure to follow us at https://twitter.com/Elixicure
Safe Harbor Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Rodedawg International Industries, Inc.
Rodedawg International Industries, Inc.
1-800-793-0355
ir@buddinghorizon.com
$SMME News: SmartMetric says its Gen4 Self Powered Biometric Finger Scan Card Is Perfectly Designed to Meet the Needs of the 518 Million Credit Cards Issued in the United States
February 6, 2024
NEW YORK--(BUSINESS WIRE)-- SmartMetric, Inc. (OTC: SMME) A fingerprint scan credit card is a type of biometric card that uses a built-in fingerprint scanner to verify the identity of the cardholder when they try to make a payment. This technology is designed to enhance the security and convenience of credit card transactions, especially for contactless payments as well as standard contact payments and ATM transactions.
Better protection of your data: Unlike PINs, fingerprint data is encrypted and is only stored in the card, bypassing the need for a central database connected to the internet, protecting a card user’s sensitive data from hackers1. Additionally, the technology safeguards against duplicated 2D and rubber fingerprints because it requires electrical capacitive sensing. In addition, the SmartMetric biometric credit/debit card has an inbuilt hardware based live fingerprint detection created by SmartMetric and only available on the SmartMetric biometric credit/debit card.
Even more convenience: Credit cards save consumers time and allow them to pay quickly. With a fingerprint scan credit card, you don’t need to remember or enter a PIN, which can speed up the checkout process and reduce the risk of forgetting or losing your PIN. At the moment the card issuing brands such as Visa and Mastercard are not proposing to eliminate the use of a PIN with a biometric card. Discussion in Europe by Banking regulators is actively talking about the doing away with the widely accepted “insecure” PIN when users use a fingerprint scan credit/debit card. Credit card networks already have the ability to turn off PIN usage which they do for some low-cost transactions such as buying a coffee. Logic would have it as biometric credit cards proliferate non-PIN usage will expand without restriction to fingerprint biometric scan cards.
Works with existing POS infrastructure: SmartMetric fingerprint scan credit cards are compatible with existing point-of-sale terminals that accept chip or contactless payments, so merchants don’t need to invest in new equipment or software to accept them. However, more recent players who are trying to test reader powered finger scan credit cards that rely on the power from the reader are trapped in having their cards not able to work at most Gas Stations, ATM’s and many restaurants that don’t have portable card readers that are brought to the table.
The stark functional deficits of non-self-powered fingerprint scan credit/debit cards compared to the SmartMetric internally powered ready to use at all times and all situations, fingerprint scan card is best explained in the following.
Non-Self Powered Fingerprint Scan Card
Only works when inserted into a card reader therefore limiting use of the card and not able to be used in all card user situations. These cards rely on the user touching the cards fingerprint sensor while the other end of the card with the contact chip is held in the reader. This allows the card to power the fingerprint scan only through the power from the card reader going into the card. So these cards are limited to readers that only partially insert the card into a reader. Otherwise, they have no power of their own to perform a fingerprint scan. Some of the places these none-powered cards will NOT work in are: ATM’s that swallow the card whole Restaurants that do not have a portable card reader but require the card to be taken from the table for transaction processing Gas station pumps that like ATM’s swallow the card whole Transit ticket dispensers that swallow the card whole Parking station ticket machines that swallow the card whole
Non-Self Powered finger scan credit or debit cards require the user to go to a bank branch to have their fingerprint scanned and then transferred onto the card via a secure fingerprint capture device. This is bothersome to the card user. It raises trust issues about having the bank involved in the capture of the user’s fingerprint. For large scale credit issuers that rely on mass mailing of new and replacement credit cards requiring their customers to have to come into a bank branch just will not work.
SmartMetric Self Powered Finger Scan Card
The SmartMetric self-powered finger scan card because it has its own internal rechargeable power, scans the cared user’s finger prior to the card being inserted into a credit card reader. Therefore, the card is able to be used at all existing and types of credit card readers without the stark limitations of the non-self-powered fingerprint scan cards.
The SmartMetric self-powered finger scan card does not require the card user to go into a bank branch to register their fingerprint on the card. Nor does it alternatively need a separate secure card reading device to be sent out to the card user for in home fingerprint download into the card. The SmartMetric finger scan card user simply touches the cards fingerprint sensor four (4) times an instantly their fingerprint is scanned and securely stored inside the card. No user friction. Instant fingerprint capture and store because the card is self-powered and acts immediately as a fingerprint scanner.
Mass credit card issuers who rely on mail distribution for the credit cards need not to change the way they do business. SmartMetric finger scan cards are easily shipped to homes through the mail and without fuss or user friction are easily set up for future card use by the user’s fingerprint.
The SmartMetric self-powered finger scan card works at ALL card readers such as: ATM’s Restaurants that take the card from the table to process (user touches the sensor which turns on the card for up to 8 minutes giving the table server enough time to have the card processed) Gas pumps Parking ticket vending machines Transit ticket vending machines
“Because of the limitations of the user and card issuer experience we believe that trials and testing of the non-self-powered cards under way in Europe are doomed to failure. Much like inferior electric vehicles are failing in the market while Tesla continues to grow exponentially with its model Y becoming the biggest selling vehicle globally. Failed poorly thought-out products fail because no one wants them while it doesn’t distract from new innovations success trajectory when the new innovators get the product to align with customers expectations,” said SmartMetric’s President and CEO, Chaya Hendrick.
It has taken years of research and development to perfect the internal power system within the SmartMetric finger scan card. Millions of dollars in research and development have been invested to create the only card of its kind in the world that will work at all card readers. A card that is simple to download your fingerprint into the card at home without the fear and inconvenience of going somewhere else to have your fingerprint scanned and stored into the card.
The SmartMetric finger scan card is light years ahead and brings the reality of full biometric security technology to the ubiquitous credit and debit card world.
Credit cards still dominate the way consumer make payments. Non credit card payments such as phones account for less than 5% of payment transactions while the majority of transactions are done using either a credit or debit card.
According to a report published by Forbes Adviser on March 9, 2023 “Over the past year, nearly half the population (47.5%) opened at least one new account, bringing the total number of accounts to over 518 million by the end of 2022.” 1
The mass market version of the SmartMetric Gen4 biometric credit card is now under manufacture following the successful testing of the cards new and advanced internal operating system on the new card hardware platform.
Currently the card is under manufacture which involves the electronic assembly and separately the cards lamination turning it into a credit card is underway in Asia. The cards internal software including its operating system has been tested by the SmartMetric group of engineers in Tel Aviv, Israel.
“While we have experienced unbelievable challenges and delays, we are very excited about being able to very soon show our finished mass production biometric finger scan card to the world,” said Chaya Hendrick.
We are protected by issued patents in the United States with pending patents in Asia and Europe and other parts of the World.
By far our biggest patent protection revolves around issued design patents granted by the USPTO (United States Patent and Trademark Office) that grant protection against any product design such as a smart card or credit chip card that has in any one of multiple variations a fingerprint sensor on it. “None of the other biometric card manufacturers who in our opinion are wasting their time with an inferior none self-powered card, will be able to sell such cards in the United States because of the issued patents,” said Chaya Hendrick.
“Design Patents are easily enforced and the owner or licensee of such patents can have offending products seized at a port of entry or at a place of business in the USA without much effort,” said Chaya Hendrick.
Utility patents can take years of legal fighting however design patents are based on does the product look like what is patented in the design patent and if so then it is infringing.
“We are confident that if a Bank in the USA wants to issue biometric finger scan cards in the USA that have a chip and a fingerprint sensor on them, then they will need to deal with SmartMetric,” said Chaya Hendrick.
To view the SmartMetric Biometric Card please follow this link - Video of the SmartMetric Biometric Card.
To view the company website: www.smartmetric.com
1 Credit Card Statistics And Trends 2024 – Forbes Advisor
Safe Harbor Statement: Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Also such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Factors that may cause actual results to d iffer materially from current expectations include, among others, if we are unable to access the capital necessary to fund current operations or implement our plans for growth; changes in the competitive environment in our industry and the markets where we operate; our ability to access the capital markets; and other risks discussed in the Company's filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, which filings are available from the SEC. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Investors and security holders are urged to carefully review and consider each of SmartMetric Inc. public filings with the SEC, including but not limited to, if applicable, Annual Reports on Form 10-K, proxy statements, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240206872799r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206872799/en/
SmartMetric, Inc.
Chaya Hendrick
Tel: (702) 990-3687
Mobile: (305) 607-3910 (Pacific Time)
ceo@smartmetric.com
http://www.smartmetric.com
Source: SmartMetric, Inc
$AVRW is set for a record sales and revenue growth year in 2024 based on all the positive groundwork that has been laid to date. The company's Seratopoical Revolution brand has clearly been demonstrated as top quality in terms of its formulations and performance, especially with the very high level endorsements that have been presented.
$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter
From this article:
– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.
– Company Currently Holds 15 Patents.
– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.
– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.
– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.
– Q3 Net Revenue Increased Sequentially from Q2 2023.
– Sales Expected to Increase Significantly During Q4 and Into 2024.
– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.
– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.
– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns
$LLLI: Lamperd Less Lethal Welcomes Talented New Sales Representatives to Directly Market Advanced Riot Control and Other Crisis Response Products
Source: https://www.facebook.com/lamperdlesslethal
SARNIA, ON / November 27, 2023 -- Lamperd Less Lethal, Inc. (OTC PINK:LLLI), an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies worldwide, has added two new Sales Representatives who are experienced and well versed in modern marketing techniques. These new additions to the Lamperd team will be making direct marketing efforts to raise awareness and close sales on the company’s full product line of advanced less lethal products which are optimized for effectiveness and safety in applications for riot control and other crisis response situations.
Maria Edison holds an Honors Bachelor of Commerce Degree from McMaster University. She served as a Market Analyst as well as a Media and Communications Resident for multiple international clients. Ms. Edison has sales experience on multicultural teams, supporting business-to-business and business-to-consumer sales efforts. She is multi-lingual utilizing English, French, Russian and Mandarin Chinese language skills to provide personalized service to a range of international clients.
Daniel Almeida holds an Honors Bachelor of Philosophy Degree from McMaster University. He served as President of the McMaster University Shooting Sports Club, where he secured sponsorships and organized shooting events for 100+ club members. An avid shooter, Mr. Almeida competes in shooting competitions in South Ontario and sells firearms from his personal collection. His experience and expertise in the field of firearms and shooting provides an excellent correlation to the Lamperd product line.
CEO Barry Lamperd stated, “With the rising need for effective security solutions we continue to see today in response to crisis situations of every kind, Lamperd certainly can use the direct sales and marketing contributions of Maria Edison and Daniel Almeida at this time. Both of these new Sales Representatives will be raising awareness in the security products market place about the wide range of solutions that the Lamperd Less Lethal line offers, with special emphasis on our company’s advantages of highest quality, versatility, effectiveness and safety. I am looking forward to working closely with both Maria and Daniel as they begin their efforts to reach out to security products customers on all levels with the aim of closing new sales in the most efficient way for everyone involved.”
About Lamperd Less Lethal:
Lamperd Less Lethal, Inc. (LLLI) is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 12 Gauge, 37mm & 40mm launching systems and a variety of different riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors. For more information visit: http://www.lamperdlesslethal.com
This press release contains forward-looking statements relating to Lamperd Less Lethal, Inc. Lamperd Less Lethal, Inc. undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public
the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact: Lamperd Less Lethal, Inc.
Barry Lamperd, President & CEO
(519) 344-4445
Email: info@lamperdlesslethal.com or sales@lamperdlesslethal.com
Company Website: http://www.lamperdlesslethal.com
Lamperd Less Lethal on Facebook: https://www.facebook.com/lamperdlesslethal
Lamperd Less Lethal on Twitter: https://www.twitter.com/LLLI_LessLethal
Barry Lamperd on Twitter: https://www.twitter.com/lamperd_llli
$SITS: Southern ITS International, Inc. Subsidiary, Pure Oil & Gas, Inc., Reports on Oil Production Numbers and Announces a New 4-Well Drilling Project in Texas
Palm Desert, California, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Southern ITS International, Inc. (Pink Open Market: SITS) proudly announces a significant achievement for its subsidiary, Pure Oil & Gas, Inc., as it began sales of oil produced by one of its wells in Texas. Production in October yielded three loads of oil—510 barrels—which has been collected and sold to BML Inc.
This success sets the stage for Pure Oil & Gas, Inc.’s next venture – a four-well drilling project in Texas.
The first new well is scheduled to begin drilling in the first week of December 2023, with production anticipated to commence within four weeks of the start of drilling operations. Funding for this new project has been secured.
Jeremy Larsen, President of Pure Oil & Gas, Inc. stated, “We are thrilled to announce our successful entry into the Texas oil reserves and look forward to the promising opportunities that lie ahead with our upcoming four-well drilling project. Our strategic location in Texas provides us with a valuable resource base, and we are confident that our collaboration with ICS Energy will contribute to the efficiency and success of our drilling operations.”
Pure Oil & Gas, Inc. has partnered with ICS Energy, LLC, an experienced driller-operator with extensive expertise in the regional geological landscape. This collaboration aims to optimize operations and bolster Pure Oil & Gas's position in the energy sector.
About Pure Oil & Gas, Inc.
Pure Oil & Gas, Inc. focuses on leveraged oil and gas acquisitions as a key strategy for growth and establishing a strong position in the industry. Supported by its parent company, Southern ITS International, Inc., Pure Oil & Gas leverages financial flexibility provided by its parent to acquire leases, producing wells, oil services companies, and new oil industry technology.
About Southern ITS International, Inc.
Southern ITS International, Inc., through its subsidiary companies, currently has operations focused on a wide variety of fields, including oil and gas exploration and development, clothing, and e-commerce fulfillment. We intend to expand upon our current base of operational companies and to increase our ownership and/or control of a portfolio of highly successful businesses. As a holding company, Southern ITS International continues to be in the market to acquire a stake in various companies, both public and private, which will complement its current operations. Our mission includes establishing a robust Direct-to-Consumer (DTC) and Business-To-Business (B2B) network, harnessing the potential of e-commerce across an array of diverse sectors, including manufacturing, distribution, and product sales. We have put in place an experienced management team that is continuing to build a diverse portfolio, buying entire companies, or interests therein, involved in technology, oil and gas, manufacturing, real estate, and other sectors, which will then become operating subsidiaries of Southern ITS International.
Precautionary and Forward-Looking Statement
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may" "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of several factors, and other risks identified in the Company's disclosures or filings with the SEC or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like Southern ITS International, Inc. are inherently volatile and risky, and that no investor should buy this stock unless they can afford the loss of their entire investment.
$IVDN (16 million float): Sales are just starting to pick up steam now. Review the latest news below which details the multiple new customer accounts for the company's superior, energy saving Insultex insulation, who are discovering this advanced product and placing orders for the first time.
LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
$EDXC News: Endexx Secures Reorder for Non-Nicotine Vape Product HYLA From Italy
$400,000 Reorder Highlights HYLA's Accelerating Product Demand
CAVE CREEK, AZ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Endexx(R) Corporation (OTCQB: EDXC), a provider of innovative plant-based wellness and nutritional products, today announced it has secured a reorder for its non-nicotine based vape product, HYLA, from its distributor in Italy.
This $400,000 reorder represents a mix of the current DOPA 1200 puff device and the new 4500 puff device. The new 4500 device is awaiting final permit for Italy and will be shipped in our First Fiscal Quarter 2024. The reorder marks the strengthening of our relationships with our distributors and continues to show accelerated demand for HYLA products worldwide.
"For HYLA, securing this reorder in Italy not only underscores the demand for non-nicotine vape products, but also reaffirms the strength and vitality of our distribution relationships," said Todd Davis, CEO of Endexx Corporation. "As we continue to navigate the global marketplace, it's evident that our leadership in "Science and Compliance(C)" resonates deeply with our international partners and consumers."
For questions, information, or to set up a meeting with management, please contact IR@Endexx.com
www.endexx.com & www.cbdunlimited.com
www.tryhyla.com
About Endexx Corporation
Endexx Corporation develops and distributes all natural, plant-derived wellness products and topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health. www.endexx.com
Hyla currently markets its proprietary non-nicotine, guarana and L-Dopa-based vape products in a wide variety of flavors. The Hyla device is the first non-nicotine vape product to be produced in this manner in the United States and provides an unprecedented 4,500 puffs per device. Hyla is currently being distributed in 10 countries and has signed distribution agreements with an additional nine countries. www.tryhyla.com
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
No Offer or Solicitation. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and, where applicable, the requirements under the securities laws of any other applicable jurisdiction.
For further information, please contact:
Endexx Corporation
IR@Endexx.com
480-595-6900
$VNUE: Sporting Events Expansion with the Aid of Collective Sports Agency for Established Music Technology Company Serving Top Artists and Venues of All Sizes; VNUE, Inc. (Stock Symbol: VNUE)
Click here:
https://digitaljournal.com/pr/news/getnews/sporting-events-expansion-with-the-aid-of-collective-sports-agency-for-established-music-technology-company-serving-top-artists-and-venues-of-all-sizes-vnue-inc-stock-symbol-vnue-
Increasing Orders and Insider Share Purchase; Patented Evacuated Cell Insulation; Innovative Designs: Stock Symbol: IVDN
Link:
https://www.einpresswire.com/article/637864225/increasing-orders-and-insider-share-purchase-patented-evacuated-cell-insulation-innovative-designs-stock-symbol-ivdn
$LLLI: Lamperd Less Lethal, Inc has been serving the needs of law enforcement, corrections, military and other security forces for decades with only the highest of praise from all of its customers. You can also see the official letters of endorsement and recognition issued to Lamperd from the Canadian government on the company's website here: https://lamperdlesslethal.com/government-endorsement/
$LLLI: Lamperd Less Lethal has developed a superior line of face shields for a range of different applications.
See all the details on the LLLI website at this direct link: https://lamperdlesslethal.com/product-category/face-shields/
This well designed product line can become a new and significant course of sales and revenue for Lamperd.
"As reported cases of COVID-19 and hospitalizations increase, companies and universities are considering mask mandates for indoor facilities. According to the latest statistics from the CDC COVID-19 Data tracker, which covers August 6 through August 12, there were 12,613 hospital admissions—an increase of 21.6% from the most recent week. During that same week, deaths were a reported 1.3%, which was an increase of 8.3% from the previous week."
https://www.contagionlive.com/view/are-masks-making-a-comeback-
$AMIH 8KA: Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On August 15, 2023, our Board of Directors of American International Holdings Corp., approved a change in fiscal year end of our Company from December 31 to June 30. The Board’s decision to change the fiscal year end was to capture the post reverse merger by way of the Share Exchange Agreement with Cycle Energy Corp and Marble Trital Inc., the sole shareholder of Cycle Energy Corp. completed on February 15, 2023.
Following such change, the date of the Company’s fiscal year end is June 30, 2023. The Company will file an annual report on Form 10-K for the six month period ended June 30, 2023 to cover such transition period.
LINK:
https://www.otcmarkets.com/filing/html?id=16869785&guid=jZN-k6NQcNpnJth
$AMIH in the oil exploration and development field has high earnings potential ahead. You don't attract multi-million dollar funding in today's frugal investment environment unless you have a business plan that inspires real confidence.
Funding Commitment of Up To $20 Million https://finance.yahoo.com/news/american-international-holdings-corp-receives-132000450.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$AITX's Subsidiary, Robotic Assistance Devices, to Host 'Police Day' July 13, 2023, Featuring Demonstrations of RADDOG(TM)
Detroit, Michigan, June 27, 2023 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (the "Company") (OTCPK:AITX), a global leader in AI-driven security and productivity solutions along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced that it will be hosting 'Police Day', a hands-on event for law enforcement agencies and first responders. The event will be held at the Company's manufacturing facility, the 'REX', located in Ferndale, Michigan on Thursday July 13, 2023, from 10:00am to 11:30am ET.
The event is meant to showcase the RADDOG family of robots to area law enforcement personnel that may be considering adding advanced robotics to their force. RAD recently announced that it is taking pre-orders for RADDOG 2LE, specifically designed for law enforcement applications. RADDOG 2LE is a critical evolution of quadruped robotics positioned to improve the capabilities of law enforcement agencies and enable them to apply practical robotics for a variety of tasks. With its agile quadruped (four-legged) design and cutting-edge external accessories, RADDOG 2LE empowers officers to conquer challenging terrain, reach inaccessible areas, and navigate through dangerous environments.
RAD is also expected to introduce RADDOG 1LE at the Police Day event. This unit includes RAD's RADPack(TM) on a smaller quadruped and will have an entry-level price point that is expected to be accessible to most law enforcement agencies.
Troy McCanna, RAD's Chief Security Officer and a former FBI Agent with extensive experience as a Multi-Jurisdictional Task Force Coordinator/Supervisor, commented on the event, "RADDOG is the force-multiplier that I wish I had by my side during my time in service. At the Police Day event, I look forward to presenting RADDOG to my former colleagues. Their early response to the dog's availability has been overwhelming. Now they'll have a chance to see it up close and even operate it."
Detroit area law enforcement agencies and other first responders are encouraged to attend. To register for the event, please visit www.tinyurl.com/hts36w5r. The event is closed to the public, only approved registered guests may attend.
The RADDOG quadruped (dog-style) robots used in the show are similar to RADDOG 2LE units. The "Stars on Mars" RADDOGs perform the duties of the mission's security robots, executing field reconnaissance and surveillance, as well as being companions to the crew members.
RAD's proprietary RADPack on RADDOG 2LE, and the highly anticipated RADDOG 1LE, offers unique features, specifically including an interactive touch screen located at the front of the quadruped. This interface facilitates smooth, high-definition video communication between remote law enforcement officers and individuals within the robot's vicinity. Complemented by integrated microphones, powerful audio speakers, and front headlights, the RADDOG family of robots for law enforcement possesses an array of capabilities to effectively engage with and capture the attention of those it may confront.
"I am so proud of all that we've designed into RADDOG that I can't wait to present it to our esteemed guests at Police Day," said Steve Reinharz, CEO of AITX and RAD. "We are planning on making this an amazing event where law enforcement personnel can fully review all of RADDOG's capabilities, features and costs and be in the position to place their initial orders."
RADDOG 2LE is scheduled to begin shipping in late July. Complete specifics of its capabilities, features and other details can be found at www.raddog.ai and www.radsecurity.com.
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers this tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit http://www.aitx.ai, http://www.radsecurity.com,http://www.stevereinharz.com, http://www.radgroup.ai, http://www.raddog.ai, and http://www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
###
Steve Reinharz
949-636-7060
@SteveReinharz
$IVDN Featured in Seeking Alpha: "IVDN bags orders for insulation solutions from Midwest U.S. customers"
Jun. 01, 2023 2:31 PM ET Innovative Designs, Inc. (IVDN) By: Ahmed Farhath, SA News Editor
Innovative Designs (OTCQB:IVDN) said it received new orders for its Insultex House Wrap insulation solution from two separate customers in the Midwest region of the U.S.
Link: https://seekingalpha.com/pr/19354336-innovative-designs-inc-receives-significant-new-orders-for-unmatched-insultex-house-wrap-from?hasComeFromMpArticle=false&source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link%257Cfirst_level_url%253Anews
$KRTL ~ KRTL International Corp. had three team members participate as advisors alongside with Park Kyung-il, a professor of horticulture at Yeungnam University, and two professors in the evaluation of the hemp cultivation division of the Industrial Hemp Special Regulatory Free Zone in South Korea.
$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore
$KRTL ~ KRTL International Corp. had three team members participate as advisors alongside with Park Kyung-il, a professor of horticulture at Yeungnam University, and two professors in the evaluation of the hemp cultivation division of the Industrial Hemp Special Regulatory Free Zone in South Korea.
$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore
$LLLI and $MMMW recent news for global demand technologies.
$KRTL ~ KRTL International Corp. had three team members participate as advisors alongside with Park Kyung-il, a professor of horticulture at Yeungnam University, and two professors in the evaluation of the hemp cultivation division of the Industrial Hemp Special Regulatory Free Zone in South Korea.
$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore
$LLLI: Recent news shows us the company is playing an important role in the global market for advanced security solutions.
Lamperd Less Lethal Receives Order and Full Payment for Special Munitions Rounds from New International Customer
May 31, 2023
https://www.otcmarkets.com/filing/html?id=16697081&guid=ZRT-kFZ0QRA5dth
Lamperd Less Lethal is Prepared to Deliver Advanced Riot Shields in a Range of Sizes and Types with Quickest Order Fulfillment Thanks to In-House Production
May 2, 2023
https://www.accesswire.com/752283/Lamperd-Less-Lethal-is-Prepared-to-Deliver-Advanced-Riot-Shields-in-a-Range-of-Sizes-and-Types-with-Quickest-Order-Fulfillment-Thanks-to-In-House-Production
$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore
$KRTL Lakewood, CO, May 30, 2023 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC:KRTL), an innovator and pioneer in developing industry-leading cross-over tradecraft and proprietary technology in the hemp, cannabis, psilocybin, and alternative wellness sectors, announces that its wholly owned subsidiary, KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
https://www.stocktitan.net/news/KRTL/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-9gtfkgeffnh3.html
$KRTL Axiom utilized the data to complete a full-service package including data acquisition, processing, analysis, technical reporting, and claim management.
$KRTL ~ KRTL International Corp. had three team members participate as advisors alongside with Park Kyung-il, a professor of horticulture at Yeungnam University, and two professors in the evaluation of the hemp cultivation division of the Industrial Hemp Special Regulatory Free Zone in South Korea.
$CDSG EXTENDS LITHIUM NORTH ZONE OVER 3.6 MILES WITH HIGH GRADE SAMPLES INCLUDING 4.02% LI2O
Las Vegas, NV., May 24, 2023 (GLOBE NEWSWIRE) -- Titan Lithium Inc., (OTC Markets: CDSG) (the "Company" or "CDSG") is pleased to announce strong Lithium geochemical sampling results from the continuation of the surface sampling program at the company's huge Titan 1 lithium property in Tanzania.
As part of our extensive geochemical sampling program designed to define the boundaries of the massive Titan 1 ("T1") Lithium discovery, extensions of the T1 survey were implemented by our field crews both to the north and south of the previously reported soil geochemical survey line results. Soil samples all consistently removed from the B soil horizon, from a depth of 6 to 10 inches.
The newly received results average 8,530 ppm lithium and occur at a distance of 3.65 miles (5.87kms) north of the former northernmost sample. The lowest grade sample in the area was still highly anomalous at 700 ppm Li, while the highest-grade value returned 4.02% Li2O (18,700 ppm Li).
The company has previously divided the massive T1 anomaly into a North and South Block, with the south block anomaly averaging 4,318 Li ppm over a full 17 square miles (44 sq kms). Both areas are underlain by a thick volcano-sedimentary sequence deposited by rift related volcanism, the source of lithium in the region. Work is still on-going to define the size and grade of the North Block.
Craig Alford, MSc, PGeo, and CEO of the Company, a Qualified Person under NI 43-101, noted "Our team was both excited and surprised by the high grades encountered in this new area so far to the north. We will continue to examine and develop the area which is proving itself to be of the highest grade and size compared to its sedimentary-style competitors."
Rigorous Quality control of the samples was maintained and all samples were prepared and analyzed at the independent and ISO 9001 certified African Minerals and Geosciences Centre (AMGC) in Dar es Salaam.
About the Company: China Dongsheng International Inc. (OTC Markets: CDSG), through its wholly owned subsidiary Titan Lithium Inc., is a lithium explorer and developer.
Contact:
Harp Sangha-Chairman
harp@titanlithiuminc.com
+1-702-595-2247
http://www.titanlithiuminc.com
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission.
$HMBL The commercial division has the first government approved wallet in the U.S.
$AITX's Subsidiary, Robotic Assistance Devices, Signs 5 New Dealers
Detroit, Michigan, May 24, 2023 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (the "Company") (OTCPK:AITX), a global leader in AI-driven security and productivity solutions along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced that it has signed 5 additional authorized dealers since the last public dealer announcement. These dealers are located throughout the continental U.S. and the state of Hawaii.
RAD's five new authorized dealers are:
Combination Security headquartered in Cassopolis, Michigan.
System Integrations with offices in Memphis, Nashville, and Lebanon, Tennessee.
Huffmaster Protective Services Group based in Clawson, Michigan
V Force Security, located in Sacramento, California.
Site Management Services headquartered in Honolulu, Hawaii.
The addition of these 5 authorized dealers brings the total number of RAD dealers to 63.
"Security technology with AI is the future, and the market for RAD solutions is right now," said Shane Kurihara, Managing Partner, Communications and Technology Director at Site Management Services. "I am especially excited to learn more about RADDOG now that I've seen it on commercials for the TV show 'Stars on Mars'. Our clients are eager to go RAD!"
The June 5th debut of "Stars on Mars" on FOX is highly anticipated and expected to attract a significant audience. The appearance of RADDOG on this series will potentially further strengthen the Company's position as a leading provider of AI-driven security and productivity solutions. RAD expects to release the full details of RADDOG shortly.
"It's a very positive trend that RAD continues to attract new dealers, each bringing new opportunities and clients," stated Mark Folmer, CPP, PSP, FSyI, President of RAD. "The security challenges that RAD addresses, whether it's guard staffing, rising costs, or out of control crime, are affecting virtually every industry. These prominent regional dealers have the necessary direct relationships with the corporate clients that are actively seeking solutions."
According to Folmer, RAD's authorized dealers must obtain a demonstration device to showcase to their clients and potential customers. The effectiveness of RAD's unique 'security-in-a-box' strategy can be efficiently demonstrated by new dealers through the use of a ROSA security robot. ROSA is renowned for its simple installation process and user-friendly dashboard.
"Since taking a demonstration ROSA upon signing as an authorized dealer, V Force Security has already moved forward and has ordered a RIO for a client," Folmer added.
"A thriving network of dealers is essential for attaining market success," stated Steve Reinharz, CEO of AITX and RAD. "RAD's impressive array of dealers not only grants us entry to new customer segments but also enables us to broaden the Company's scope and enhance the visibility of our products. I am genuinely delighted that RAD's dealer network comprises esteemed regional dealers and security industry leaders."
ROSA is a multiple award-winning, compact, self-contained, portable, security and communication solution that can be installed and activated in about 15 minutes. Like other RAD solutions, it only requires power as it includes all necessary communications hardware. ROSA's AI-driven security analytics include human, firearm, vehicle detection, license plate recognition, responsive digital signage and audio messaging, and complete integration with RAD's software suite notification and autonomous response library. Two-way communication is optimized for cellular, including live video from ROSA's dual high-resolution, full-color, always-on cameras. RAD has published three Case Studies detailing how ROSA has helped eliminate instances of theft, trespassing and loitering at car rental locations and construction sites across the country.
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers this tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit http://www.aitx.ai, http://www.stevereinharz.com, http://www.radsecurity.com,http://www.radgroup.ai, and http://www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
###
Steve Reinharz
949-636-7060
@SteveReinharz
$HMBL Pursuant to the Equity Financing Agreement, Pacific Lion has agreed to purchase up to $20,000,000 of HUMBL common stock following the receipt of put notices from HUMBL and subject to certain conditions. Pursuant to the Registration Rights Agreement entered into in connection with the Equity Financing Agreement, HUMBL agreed to file a registration statement to register the common stock issuable under the Equity Financing Agreement. Following the effectiveness of the registration statement, if HUMBL elects to cause Pacific Lion to purchase shares, the shares will be purchased at a 15% discount to the lowest closing trade price of HUMBL’s common stock in the prior 10 trading days. The Equity Financing Agreement with Pacific Lion replaces the Equity Financing Agreement previously entered into with GHS Investments, LLC, which has been terminated.
https://www.nasdaq.com/press-release/humbl-receives-funding-commitment-of-up-to-%2421-million-as-an-initial-step-in-a
$HMBL HUMBL Selected as Official Digital Wallet and Ticketing Technology Provider for “Motherland Samoa 2023” Festival
https://finance.yahoo.com/news/humbl-selected-official-digital-wallet-185500287.html
$AITX Launches Artificial Intelligence Powered Chatbot for Investor Relations
Detroit, Michigan, May 19, 2023 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (the "Company") (OTCPK:AITX), a global leader in AI-driven security and productivity solutions today announced the deployment of the first of three artificial intelligence powered large language models to enhance investor engagement and provide simplified access for investor's due diligence and fact-checking as it relates to $AITX.
The Company revealed its plans to utilize advanced OpenAI Large Language Model technology across its various online platforms in a press release on May 4, 2023. GPT, short for Generative Pre-trained Transformer, is a powerful AI language model developed by OpenAI. GPT-4, the latest version, is known for its exceptional ability to understand and generate human-like text, making it ideal for a wide range of applications.
The initial deployment is located on the Company's website aitx.ai. On the site, visitors will engage with RADDOG(TM) performing the duties of chat moderator and curator of all requested, publicly available, Company information.
"This should be a valuable and helpful tool for investors, followers and all interested parties, looking for reliable data on AITX," said Steve Reinharz, CEO of AITX. "Ensuring easy access to company information is a responsibility we take seriously, and this AI chatbot will help considerably. It will be fascinating to see how it gets better in the coming months as we start giving it transcribed weekly videos and more data."
In the near future, the Company will be rolling out additional GPT solutions including:
Sales and Prospect Aid (SPA): SPA will offer an intelligent, AI-assisted platform for RAD's sales team, accelerating the sales process and enhancing customer relationships using existing resources. By providing real-time support and tailored solutions, SPA could empower AITX sales representatives to close deals more efficiently and effectively.
Technical Troubleshooting and Support (TTS): TTS is a powerful AI-driven technical assistance platform designed to provide instant, accurate solutions to the technical challenges that RAD's clients may face. With TTS, the Company aims to minimize downtime and maximize productivity for its clients.
Reinharz added "It's foreseeable that every company, every website in the future will be supported by these advanced AI tools. We are pleased to be one of the first to fully implement these to the benefit our of investors, clients, and followers."
AITX's embrace of GPT technology serves as a testament to the Company's unwavering dedication to leading the charge in AI-driven solutions. Moreover, the implementation of GPT technology is projected to elevate customer satisfaction by delivering enhanced capabilities and tailored experiences. Furthermore, AITX's pioneering approach sets the stage for continuous innovation and breakthroughs in the ever-evolving AI industry.
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers this tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication, including the deployment of artificial intelligence powered large language models, should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staffs and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit http://www.aitx.ai, http://www.stevereinharz.com, http://www.radsecurity.com,http://www.radgroup.ai, and http://www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
###
Steve Reinharz
949-636-7060
@SteveReinharz
CDSG typical hyped mining project
Mineral content are only projection and not proven
Company even qualifies it HIGHLY SPECULATIVE
DD HARPREET SINGH SANGHA, also dubbed mini-Madoff by Bob Moriarty
Buyers beware
$CDSG Video Presentation - Titan Lithium Project
https://titanlithiuminc.com/titan-project-video-presentation/
------------------------------------------------------------------------------------------------------------------
China Dongsheng International Inc. (OTC Markets: CDSG), through its wholly owned subsidiary Titan Lithium, Inc., is a lithium explorer and developer with operations in Nevada, USA and The United Republic of Tanzania.
Contact:
Harp Sangha-Chairman
harp@titanlithiuminc.com
+1-702-595-2247
http://www.titanlithiuminc.com
$CDSG Presenting here: Metals & Mining Hybrid Investor Conference Agenda Announced for May 11th
Link:
https://finance.yahoo.com/news/metals-mining-hybrid-investor-conference-123500721.html
China Dongsheng International Inc. (OTC Markets: CDSG), through its wholly owned subsidiary Titan Lithium, Inc., is a lithium explorer and developer with operations in Nevada, USA and The United Republic of Tanzania.
Contact:
Harp Sangha-Chairman
harp@titanlithiuminc.com
+1-702-595-2247
http://www.titanlithiuminc.com
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4860
|
Created
|
05/05/13
|
Type
|
Free
|
Moderator StockMasterTalk | |||
Assistants Aufklaerung |
Posts Today
|
0
|
Posts (Total)
|
4860
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |